Pulmonary Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

ThePulmonary Drugs Market is Segmented by Drug Class, Indication (Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), Distribution Channel, and Geography

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Global Pulmonary Drugs Market is expected to witness a CAGR of 5.4% during the forecast period. Certain factors that are driving the market growth include the rising prevalence of pulmonary diseases and the growing geriatric population.

Pulmonary diseases affect the airways and other parts of the lungs for a long duration of the period. Respiratory symptoms are among the major causes of consultation with doctors and physicians in primary health care centers. 

Some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). Pulmonary diseases affect more than 1 billion people, globally, as per the Global Asthma Report, 2018. Asthma is one of the largest contributors to this figure, affecting children, adults, and elderly people. There is a high prevalence of severe asthma in the emerging markets, such as MEA and Latin America, compared to the mid-range of prevalence in North America, Europe, and Asia-Pacific countries. 

Another reason for the increased prevalence of respiratory diseases is the excessive environmental pollution in metropolitan cities and industrials lands. In addition, second hand smoke exposure also leads to serious respiratory diseases.

Scope of the Report

As per the scope of the report, pulmonary diseases refer to the types of diseases that affect the lungs and other parts of the respiratory system. Pulmonary diseases may be caused by infection, by smoking tobacco, or by breathing in secondhand tobacco smoke, radon, asbestos, or other forms of air pollution. Pulmonary drugs is the branch of medicine that deals with the causes, diagnosis, prevention and treatment of such pulmonary diseases.

By Drug Class
Beta-2 Agonists
Anti-cholinergic Agents
Oral and Inhaled Corticosteroids
Anti-leukotrienes
Antihistamines
Monoclonal Antibodies
Combination Drugs
Others
By Indication
Asthma
COPD (Chronic Obstructive Pulmonary Disease)
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Treatment for Chronic Obstructive Pulmonary Disease is Expected to Grow with High CAGR over the Forecast Period

Pulmonary drugs like bronchodilators are very common for COPD treatment and symptoms. Bronchodilators are medications that usually come in inhalers. These medications relax the muscles around your airways. This can help relieve coughing and shortness of breath and make breathing easier. Depending on the severity of your disease, one may need a short-acting bronchodilator before activities, a long-acting bronchodilator that you use every day or both.

Moreover, the incidence cases of COPD have also increased over the years. As per a 2020 report published in the BioMed Respiratory Research Journal, the global number of COPD cases increased by 49.8% from nearly 200 million in 1990 to 299.4 million in 2017. As pulmonary drugs are vital for COPD, the increasing incidence of COPD is expected to increase the demand for therapy drugs, which is expected to help the market growth.

graph.png

North America Dominates the Market and Expected to do Same in the Forecast Period

The increasing prevalence of respiratory diseases is the major factor expected to drive the overall growth of the market over the forecast period. Also, there is a rise in per capita health expenditure in the region, which is expected to increase over the forecast period, owing to the decrease in the unemployment rate. The cases of COPD are likely to increase in the United States, owing to the higher smoking prevalence and the aging population in the country.

As per a 2019 report by the Asthma and Allergy Foundation of America, more than 11.4 million people with asthma, including more than 3 million children, reported having one or more asthma episodes or attacks in 2017. As per the report, asthma is the leading chronic disease in children. Currently, there are about 6.2 million children under the age of 18 with asthma. In 2017, 1 in 12 children had asthma. Hence all these factors coupled with high expenditure on healthcare are expected to increase care for these diseases, which will help the market growth.

Geo.png

Competitive Landscape

The global Pulmonary Drugs market is highly competitive and consists of a number of major players. Companies like AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Grifols, Merck & Co., Pfizer, Regeneron Pharmaceuticals, Sumitomo Dainippon Pharma, Teva Pharmaceuticals, among others, hold the substantial market share in the Pulmonary Drugs market.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Pulmonary Diseases

      2. 4.2.2 Increasing Burden of Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations for Product Approval

      2. 4.3.2 Side Effects Associated With Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Beta-2 Agonists

      2. 5.1.2 Anti-cholinergic Agents

      3. 5.1.3 Oral and Inhaled Corticosteroids

      4. 5.1.4 Anti-leukotrienes

      5. 5.1.5 Antihistamines

      6. 5.1.6 Monoclonal Antibodies

      7. 5.1.7 Combination Drugs

      8. 5.1.8 Others

    2. 5.2 By Indication

      1. 5.2.1 Asthma

      2. 5.2.2 COPD (Chronic Obstructive Pulmonary Disease)

      3. 5.2.3 Allergic Rhinitis

      4. 5.2.4 Pulmonary Arterial Hypertension

      5. 5.2.5 Cystic Fibrosis

      6. 5.2.6 Others

    3. 5.3 By Distribution Channel

      1. 5.3.1 Hospital Pharmacies

      2. 5.3.2 Retail Pharmacies

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca PLC

      2. 6.1.2 Boehringer Ingelheim

      3. 6.1.3 F. Hoffmann-La Roche Ltd.

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Grifols, S.A.

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Pfizer Inc.

      8. 6.1.8 Regeneron Pharmaceuticals, Inc.

      9. 6.1.9 Sumitomo Dainippon Pharma Co., Ltd.

      10. 6.1.10 Teva Pharmaceutical Industries Ltd.,

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Pulmonary Drugs Market market is studied from 2018 - 2026.

The Pulmonary Drugs Market is growing at a CAGR of 5.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Boehringer Ingelheim, Merck & Co., AstraZeneca PLC, GlaxoSmithKline PLC, Grifols, S.A. are the major companies operating in Pulmonary Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!